Literature DB >> 17845396

Hepatitis G virus exposure in dialysis staff.

Ali Eslamifar1, Rasool Hamkar, Amitis Ramezani, Farrokhlagha Ahmadi, Latif Gachkar, Somayeh Jalilvand, Ladan Adibi, Ali Khameneh, Shahnaz Atabak, Ramin Ghadimi, Arezoo Aghakhani.   

Abstract

Hepatitis G virus (HGV) is a blood-borne virus. Some present data demonstrate an occupational risk of HGV infection in medical staff of dialysis units. The aim of this investigation was to assess the prevalence of HGV exposure in dialysis staff. This study was performed in a main dialysis unit in Iran. In 27 dialysis staff, HGV exposure was detected serologically by the presence of anti HGV envelope protein E2 (anti-E2) by an enzyme-linked immunosorbent assay, and compared with 77 hemodialysis (HD) and 13 continuous ambulatory peritoneal dialysis (CAPD) patients. All of them were also screened for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis C antibody (anti-HCV). A low prevalence of HGV exposure was found in the dialysis staff (0%), which nearly corresponded to the prevalence of the dialysis patients (HD 3.89%, CAPD 0%). The prevalence of anti-HCV and anti-HBs in staff was 37.03% and 33.33%, respectively, which was higher than HGV anti-E2. The prevalence of HGV exposure was low in dialysis staff in our study, and was near to the prevalence of HGV exposure in dialysis patients. Therefore, it can be concluded that the occupational risk for HGV exposure in our investigation was minimal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845396     DOI: 10.1111/j.1744-9987.2007.00501.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  2 in total

1.  Occult hepatitis B infection in chronic hemodialysis patients: Comparison of results and concepts: Occult HBV in chronic hemodialysis patients.

Authors:  Amitis Ramezani; Mohammad Banifazl; Arezoo Aghakhani
Journal:  Hepat Mon       Date:  2011-02       Impact factor: 0.660

2.  Prevalence of GBV-C RNA in HIV infected individuals in Tehran, Iran.

Authors:  H Keyvani; A Mohammadi; M Haji-Abdolbaghi
Journal:  Iran J Public Health       Date:  2010-03-31       Impact factor: 1.429

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.